222 related articles for article (PubMed ID: 9650698)
1. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
Sparrow LE; Eldon MJ; English DR; Heenan PJ
Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698
[TBL] [Abstract][Full Text] [Related]
2. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry of p16 in nevi of pregnancy and nevoid melanomas.
Koh SS; Roehmholdt BF; Cassarino DS
J Cutan Pathol; 2018 Dec; 45(12):891-896. PubMed ID: 30178478
[TBL] [Abstract][Full Text] [Related]
4. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
5. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
7. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
9. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclins A and E in melanocytic skin lesions and its correlation with some clinicopathologic features.
Alekseenko A; Wojas-Pelc A; Lis GJ; Wiśniowski Z; Czerwińska M; Niewiara Ł; Litwin JA
Folia Histochem Cytobiol; 2012 Jul; 50(2):263-9. PubMed ID: 22763964
[TBL] [Abstract][Full Text] [Related]
11. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma.
de Andrade BA; León JE; Carlos R; Delgado-Azañero W; Mosqueda-Taylor A; de Almeida OP
Head Neck Pathol; 2012 Sep; 6(3):297-304. PubMed ID: 22311377
[TBL] [Abstract][Full Text] [Related]
13. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
14. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
15. p16 Range of expression in dermal predominant benign epithelioid and spindled nevi and melanoma.
Oaxaca G; Billings SD; Ko JS
J Cutan Pathol; 2020 Sep; 47(9):815-823. PubMed ID: 32330325
[TBL] [Abstract][Full Text] [Related]
16. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
17. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Flørenes VA; Maelandsmo GM; Kerbel RS; Slingerland JM; Nesland JM; Holm R
Am J Pathol; 1998 Jul; 153(1):305-12. PubMed ID: 9665492
[TBL] [Abstract][Full Text] [Related]
18. p15 Expression Differentiates Nevus from Melanoma.
Taylor LA; O'Day C; Dentchev T; Hood K; Chu EY; Ridky TW; Seykora JT
Am J Pathol; 2016 Dec; 186(12):3094-3099. PubMed ID: 27855847
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of p16 in desmoplastic melanoma.
Blokhin E; Pulitzer M; Busam KJ
J Cutan Pathol; 2013 Sep; 40(9):796-800. PubMed ID: 23808580
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Expression of p16 in Melanocytic Lesions: An Updated Review and Meta-analysis.
Koh SS; Cassarino DS
Arch Pathol Lab Med; 2018 Jul; 142(7):815-828. PubMed ID: 29939777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]